Inflammatory response: An unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy

Lancet Oncology

Volumn 4, Issue 4, 2003, Pages 224-232

  Slaviero, Kellie A ^a   Clarke, Stephen J ^b   Rivory, Laurent P ^a,b  

^a University of Sydney   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROANISOLE; ANILINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOTOXIC AGENT; DOCETAXEL; ERYTHROMYCIN; ETOPOSIDE; HEXOBARBITAL; INFLUENZA VACCINE; IRINOTECAN; MEPHENYTOIN; NAVELBINE; PACLITAXEL; PHENOBARBITAL; RECOMBINANT ALPHA INTERFERON; RIFAMPICIN; TAMOXIFEN; TAXANE DERIVATIVE; THEOPHYLLINE; TOPOTECAN; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; XENOBIOTIC AGENT; ZOXAZOLAMINE;

ASTHMA; CANCER; CANCER CHEMOTHERAPY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; HUMAN; INFLAMMATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT;

EID: 0242684607     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01034-9     Document Type: Review

References (78)

1. Levy G. Predicting effective drug concentrations for individual patients: determinants of pharmacodynamic variability. Clin Pharmacokinet 1998; 34: 323-33.
2. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590-611.
3. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40: 523-30.
4. Watkins PB, Murray SA, Winkelman LG, et al. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P450: studies in rats and patients. J Clin Invest 1989; 83: 688-97.
5. Rivory LP, Slaviero K, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients with an acute-phase response. Br J Cancer 2002; 87: 277-80.
6. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
7. Richards CD, Gauldie J. Role of cytokines in acute-phase response. In: Aggarawal BB, Puri R (Eds). Human cytokines: their role in disease and therapy. Ann Arbor: Blackwell Sciences, 1995: 223-69.
8. Cohen MC, Cohen S. Cytokine function: a study in biologic diversity. Am J Clin Pathol 1996; 105: 589-98.
9. Sporn MB. The importance of context in cytokine action. Kidney Int 1997; 51: 1352-54.
10. Spitzer JA, Zheng M, Kolls JK, et al. Ethanol and LPS modulate NF-kappaB activation, inducible NO synthase and COX-2 gene expression in rat liver cells in vivo. Front Biosci 2002; 7: 99-108.
11. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002; 4: 250-55.
12. Vener C, Guffanti A, Pomati M, et al. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis. Leuk Lymphoma 2000; 37: 333-39.
13. Mantovani G, Maccio A, Madeddu C, et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer 2002; 98: 84-91.
14. Guengerich FP. Characterization of human cytochrome P450 enzymes. FASEB J 1992; 6: 745-48.
15. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 1997; 29: 1129-88.
16. Mitani K, Fujita H, Kappas A, Sassa S. Heme oxygenase is a positive acute-phase reactant in human Hep3B hepatoma cells. Blood 1992; 79: 1255-59.
17. Fukuda Y, Sassa S. Suppression of cytochrome P450IA1 by interleukin-6 in human HepG2 hepatoma cells. Biochem Pharmacol 1994; 47: 1187-95.
18. Morel Y, Barouki R. Down-regulation of cytochrome P450 1A1 gene promoter by oxidative stress: critical contribution of nuclear factor 1. J Biol Chem 1998; 273: 26969-76.
19. Roe AL, Warren G, Hou G, et al. The effect of high-dose endotoxin on CYP3A2 expression in the rat. Pharm Res 1998; 15: 1603-08.
20. Iber H, Chen Q, Cheng PY, Morgan ET. Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site. Arch Biochem Biophys 2000; 377: 187-94.
21. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, et al. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000; 274: 707-13.
22. Beigneux AP, Moser AH, Shigenaga JK, et al. Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem Biophys Res Commun 2002; 293: 145-49.
23. Kato R, Takanaka. A, Takahashi A, Onoda K. Drug metabolism in tumor-bearing rats: activities of NADPH-linked electron transport and drug-metabolizing enzyme systems in liver microsomes of tumor-bearing rats. Jpn J Pharmacol 1968; 18: 224-44.
24. Takahashi A, Kato R. Effect of toxohormone on microsomal cytochromes and hydroxylating systems of rat liver. J Biochem (Tokyo) 1969; 65: 325-27.
25. Kato R, Takanaka A, Oshima T. Drug metabolism in tumor-bearing rats: in vivo metabolisms and effects of drugs in tumor-bearing rats. Jpn J Pharmacol 1968; 18: 245-54.
26. Rosso R, Dolfini E, Donelli MG. Prolonged effect of pentobarbital in tumor bearing rats. Eur J Cancer 1968; 4: 133-35.
27. Rosso R, Donelli MG, Franchi G, Garattini S. Impairment of drug metabolism in tumor-bearing animals. Eur J Cancer 1971; 7: 565-77.
28. Wilson JT. An investigation of the decrease in the metabolism of hexobarbital, aminopyrine and p-nitrobenzoic acid by liver from rats bearing a pituitary mammotropic tumor. J Pharmacol Exp Ther 1968; 160: 179-88.
29. Wilson JT. Hepatic drug metabolism after phenobarbital or 3-methylcholanthrene pretreatment of rats bearing a pituitary tumor. Proc Soc Exp Biol Med 1968; 128: 445-48.
30. Franchi G, Rosso R. Metabolic fate of zoxazolamine in tumor bearing rats. Biochem Pharmacol 1969; 18: 236-38.
31. Schacter BA, Kurz P. Alterations in hepatic and splenic microsomal electron transport system components, drug metabolism, heme oxygenase activity, and cytochrome P-450 turnover in Murphy-Sturm lymphosarcoma-bearing rats. Cancer Res 1982; 42: 3557-64.
32. Beck WT, Dedmon ML, Ouellette MA. Biochemical basis for impaired drug metabolism in tumor-bearing rats: evidence for altered regulation of hepatic microsomal hemeprotein synthesis. Biochem Pharmacol 1982; 31: 1535-43.
33. Boulos BM, Sirtori C. Barbiturate metabolism as affected by neoplastic disease. Clin Toxicol 1971; 4: 361-68.
34. Boulos BM, MacDougall M, Shoeman DW, Azarnoff DL. Evidence that inhibition of hepatic drug oxidation by tumors is mediated by a circulating humor. Proc Soc Exp Biol Med 1972; 139: 1353-55.
35. Bartosek I, Guaitani A, Donelli MG. Prolonged metabolism of pentobarbital in isolated perfused liver of tumor bearing rats. Biochem Pharmacol 1972; 21: 2359-62.
36. Villeneuve JP, Gerber JG, Branch RA, et al. Drug metabolism in rats bearing a pituitary mammotropic tumor. J Pharmacol Exp Ther 1979; 209: 7-11.
37. Schacter BA, Kurz P. Alterations in hepatic heme and cytochrome P-450 metabolism in Murphy- Sturm lymphosarcoma-bearing rats: implications for drug metabolism. Biochem Pharmacol 1984; 33: 815-20.
38. Meredith CG, Christian CD, Johnson RF, et al. Effects of influenza virus vaccine on hepatic drug metabolism. Clin Pharmacol Ther 1985; 37: 396-401.
39. Shedlofsky SI, Israel BC, McClain Q, et al. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994; 94: 2209-14.
40. Shedlofsky SI, Israel BC, Tosheva R, Blouin RA. Endotoxin. depresses hepatic cytochrome P450-mediated drug metabolism in women. Br J Clin Pharmacol 1997; 43: 627-32.
41. Craig PI, Tapner M, Farrell GC. Interferon suppresses erythromycin metabolism in rats and human subjects. Hepatology 1993; 17: 230-35.
42. Yamaguchi A, Tateishi T, Okano Y, et al. Higher incidence of elevated body temperature or increased C-reactive protein level in asthmatic children showing transient reduction of theophylline metabolism. J Clin Pharmacol 2000; 40: 284-89.
43. Mayo PR, Skeith K, Russell AS, Jamali F. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol 2000; 50: 605-13.
44. Frye RF, Schneider VM, Frye CS, Feldman AM. Plasma levels of TNF-alpha and IL6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 2002; 8: 315-19.
45. Piafsky KM, Borga O. Plasma protein binding of basic drugs: importance of alpha 1-acid glycoprotein for interindividual variation. Clin Pharmacol Ther 1977; 22: 545-49.
46. O'Neil WM, Gilfix BM, DiGirolamo A, et al. N-acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow? Clin Pharmacol Ther 1997; 62: 261-71.
47. Emilie D, Galanaud P. Cytokines and chemokines in HIV infection: implications for therapy. Int Rev Immunol 1998; 16: 705-26.
48. Chen YL, Le Vraux V, Leneveu A, et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994; 55: 649-60.
49. Israel BC, Blouin RA, McIntyre W, Shedlofsky SI. Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993; 36: 229-35.
50. Hassan M, Nilsson C, Olsson H, et al. The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma. Eur J Haematol 1999; 63: 163-70.
51. Islam M, Frye RF, Richards TJ, et al. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 2002; 8: 2480-87.
52. Williams ML, Bhargava P, Cherrouk I, et al. A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. Br J Clin Pharmacol 2000; 49: 485-88.
53. Rivory LP, Slaviero K, Seale JP, et al. Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res 2000; 6: 3480-85.
54. Slaviero KA, Rivory LP, Seale JP, et al. Measures of inflammatory status correlates with hepatic drug metabolism in cancer patients. Proceedings of the International Congress of Toxicology, Brisbane, Australia 2001: PA39
55. Kulmatycki KM, Abouchehade K, Sattari S, Jamali F. Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat. Br J Pharmacol 2001; 133: 286-94.
56. Tangye SG, Raison RL. Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2. Immunol Cell Biol 1997; 75: 127-35.
57. Jewell AP, Worman CP, Lydyard PM, et al. Interferon-alpha upregulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Haematol 1994; 88: 268-74.
58. Schroeder JJ, Cousins RJ. Interleukin 6 regulates metallothionein gene expression and zinc metabolism in hepatocyte monolayer cultures. Proc Natl Acad Sci U S A 1990; 87: 3137-41.
59. Snyers L, Content J. Induction of metallothionein and stomatin by interleukin-6 and glucocorticoids in a human amniotic cell line. Eur J Biochem 1994; 223: 411-18.
60. Eskandari N, Gage J, Johnson MT, Martinez-Maza O. Cytokine-mediated modulation of cisplatin sensitivity in ovarian cancer cells. Obstet Gynecol 2001; 97 (suppl 1): S2.
61. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis- diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995; 55: 4633-39.
62. Bours V, Bentires-Alj M, Hellin AC, et al. Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol 2000; 60: 1085-89.
63. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997; 17: 3-9.
64. Lind DS, Hochwald SN, Malaty J, et al. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 2001; 130: 363-69.
65. Jones DR, Broad RM, Madrid LV, et al. Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann Thorac Surg 2000; 70: 930-36.
66. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001; 20: 7342-51.
67. Milligan SA, Nopajaroonsri C. Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro. Anticancer Res 2001; 21: 39-44.
68. Broom J, Heys SD, Whiting PH, et al. Interleukin 2 therapy in cancer: identification of responders. Br J Cancer 1992; 66: 1185-87.
69. Simpson WG, Heys SD, Whiting PH, et al. Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer. Clin Exp Immunol 1995: 99: 143-47.
70. Tartour E, Blay JY, Dorval T, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multi-institutional study. J Clin Oncol 1996; 14: 1697-703.
71. De Vita F, Orditura M, Auriemma A, et al. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 1998; 5: 649-52.
72. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999; 19: 1427-32.
73. Penson RT, Kronish K, Duan Z, et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000; 10: 33-41.
74. Blay JY, Negrier, S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-22.
75. Tartour E, Dorval T, Mosseri V, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994; 69: 911-13.
76. Ingenbleek Y, Carpentier YA. A prognostic inflammatory and nutritional index scoring critically ill patients. Int J Vitam Nutr Res 1985; 55: 91-101.
77. Tartour E, Deneux L, Mosseri V, et al. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study. Cancer 1997; 79: 1401-08.
78. Goldwasser F, Burthaud X, Jasmin C, Misset J-L. Predictive value of nutritional and inflammatory status for topotecan toxicity. Proc Am Assoc Cancer Res 1998; 39: 507 (Abstr 3446).